SNM

Increased Adoption of Artificial Intelligence Across the Healthcare Industry Driving Strong Market Growth

Retrieved on: 
Wednesday, March 27, 2024
PWD, African Americans, Conditional sentence, Patient, Big data, Intellectual property, Lidar, Artificial intelligence, Certification, AMD, Risk, Sony, PALM, 3D, NIH, Treatment, Culture, Safety, OTCQB, CE marking, Weather, SSS, Prevalence, Radiology, Intelligence, Family, PLTR, Depth perception, Triage, News, Historical trauma, Cancer, AI, MDR, MPH, Butterfly, Health equity, Diagnosis, Arrhythmia, Health, Butterfly network, Growth, Patent, Perception, SNM, PTAB, AIP, FAAFP, FRCS, Medical device

In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.

Key Points: 
  • In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.
  • Mordor Intelligence continued: “The increased prevalence of cancer and the high burden of other chronic diseases are, in turn, increasing the demand for accurate diagnosis and treatment.
  • This is likely to increase the adoption of AI for early diagnosis purposes, ultimately boosting the market growth.
  • The use of artificial intelligence in the North American healthcare market is being driven by the increasing use of advanced technology in healthcare systems, the growth in funding of AI-based startups, the rising burden of chronic diseases in the country, the growing need to reduce healthcare costs, and the implementation of big data in healthcare.

Prime Insurance Company Represents Insured SNM Logistics, LLC To Fight and Win Frivolous Litigation

Retrieved on: 
Tuesday, March 19, 2024
Trucking, Logistics, Supply Chain Management, Professional Services, Transport, Insurance, Partnership, SNM, Gold, AM Best, Pain, Recreation, Neck

Rick J. Lindsey, President and CEO of Prime Insurance Company, a specialty insurance carrier, announced another winning jury verdict in defense of their insured, SNM Logistics LLC, over an alleged trucking accident in Houston, Texas.

Key Points: 
  • Rick J. Lindsey, President and CEO of Prime Insurance Company, a specialty insurance carrier, announced another winning jury verdict in defense of their insured, SNM Logistics LLC, over an alleged trucking accident in Houston, Texas.
  • The jury agreeing with Prime that the accident did not happen, gave SNM the defense verdict so that SNM owes nothing.
  • Good Trucking Companies, businesses and individuals need an insurance company willing to fight frivolous litigation.
  • Prime Insurance Company is a specialty lines insurance carrier writing business in all 50 states, U.S. Virgin Islands, Guam, and Puerto Rico.

Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Retrieved on: 
Thursday, March 14, 2024
Neurology, Medical Devices, Health, Health Technology, Medical Supplies, CE marking, Physician, Health Canada, Patient, SNM, Lead, MRI, R20, Incontinence

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval.
  • The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15™) and is paired with the same tined lead and intuitive, easy to use patient remote control.
  • The R20 represents another significant breakthrough for rechargeable neuromodulation devices and underscores Axonics’ commitment to continuous innovation.
  • The R20 received approval from the U.S. FDA in January 2023 and from Health Canada in December 2022.

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Retrieved on: 
Thursday, March 21, 2024
MRI, Patent, District court, SNM, PTAB, Complaint, ITC, Intellectual property

DUBLIN, March 21, 2024  /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

Key Points: 
  • DUBLIN, March 21, 2024 /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies.
  • Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.
  • Medtronic will now ask the federal court in the Central District of California, where Medtronic's patent infringement lawsuit is pending, to lift its stay on the lawsuit and proceed to trial on the five valid and affirmed patents so Medtronic can present its case in front of a jury.
  • "We respect the intellectual property of innovators, and our patent system exists to benefit society by encouraging the kind of innovation that Medtronic invests in.

Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Technology, Acquisition, Research, Boston Scientific, Incontinence, SNM, Patient, Investment, Video game

Gross margin was 75.4% in fourth quarter 2023 compared to 73.3% in the prior year period.

Key Points: 
  • Gross margin was 75.4% in fourth quarter 2023 compared to 73.3% in the prior year period.
  • Operating expenses were $81.7 million in fourth quarter 2023 and included $3.5 million of acquisition-related costs.
  • Net income was $6.6 million in fourth quarter 2023 compared to $0.7 million in the prior year period.
  • Adjusted EBITDA was $18.9 million in fourth quarter 2023 compared to $10.1 million in the prior year period.

Neuspera Medical, Inc. Announces Milestone Completion of 100th Implant in Its SANS-UUI Phase II Clinical Trial

Retrieved on: 
Tuesday, November 14, 2023
Urine, Safety, Depression, SAN, Woman, Exercise, SNM, OAB, Clinical trial, Patient, PNS, FDA, Overactive bladder, Disease, Freedom, Physician, Quality of life, Medical device

SAN JOSE, Calif. , Nov. 14, 2023 /PRNewswire/ -- Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, today announced the completion of the 100th implant of its Neuspera System as part of the SANS-UUI Phase II clinical trial. SANS-UUI is an international study that's evaluating the safety and efficacy of the Neuspera System, a discreet, minimally invasive implant designed to provide patients personal control and relief from urinary urge incontinence (UUI), a symptom of overactive bladder (OAB).

Key Points: 
  • SAN JOSE, Calif. , Nov. 14, 2023 /PRNewswire/ -- Neuspera Medical, Inc. , a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, today announced the completion of the 100th implant of its Neuspera System as part of the SANS-UUI Phase II clinical trial.
  • "I'm excited to be a part of this clinical trial and the potential of this minimally invasive and discreet sacral neuromodulation therapy option."
  • "We're grateful to all of the physicians and patients for their enthusiastic participation in this study," said Steffen Hovard, CEO of Neuspera Medical.
  • The Neuspera System has FDA approval for peripheral nerve stimulation (PNS) and is undergoing clinical trials as an investigational device for the use of treating UUI, a symptom associated with OAB.

GLOBAL BLACK ECONOMIC FORUM AND STARNEWS MOBILE PARTNER TO EMPOWER BLACK ENTREPRENEURS

Retrieved on: 
Friday, July 14, 2023
SNM, Growth, Partnership, Entrepreneurship, Environment, Video game, Drug, Black

LOS ANGELES, July 13, 2023 /PRNewswire/ -- The Global Black Economic Forum (GBEF) and StarNews Mobile (SNM) have announced a strategic partnership to empower Black entrepreneurs and promote collaboration among Black businesses globally.

Key Points: 
  • LOS ANGELES, July 13, 2023 /PRNewswire/ -- The Global Black Economic Forum (GBEF) and StarNews Mobile (SNM) have announced a strategic partnership to empower Black entrepreneurs and promote collaboration among Black businesses globally.
  • Announcing a partnership set to empower Black entrepreneurs and promote collaboration among Black businesses globally.
  • Through our partnership with the GBEF, we can facilitate a global dialogue among Black entrepreneurs and connect them with US Black businesses."
  • The GBEF is renowned for its work in promoting economic empowerment for Black communities worldwide and creating an environment where Black entrepreneurs can thrive.

Axonics Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 1, 2023
General Health, Health Technology, Health, Medical Devices, Telephone, SNM, Webcast, Incontinence, EBITDA, FDA, Acquisition, Patient, Investment, Physician, Pharmaceutical industry, Cryptocurrency, Beauty salon, Video game, Axon Enterprise

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2023.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2023.
  • In the first quarter, we received FDA approval and commercially launched the Axonics R20™ , our fourth-generation rechargeable SNM system that requires recharging just once every six to ten months for one hour.
  • Axonics has updated its fiscal year 2023 revenue guidance as follows:
    Total company revenue of $348 million, an increase of 27% compared to fiscal year 2022.
  • Axonics will host a conference call today at 4:30 p.m. Eastern Time to discuss financial results and recent business developments.

Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation

Retrieved on: 
Monday, April 24, 2023
Pharmaceutical, Health, Medical Devices, Anatomy, Physician, Learning curve, SNM, PNE, Acquisition, Patient, Fluoroscopy, FDA, Sacrum, Software, Medical imaging, Radian, Axon Sports

Physicians determine a patient’s eligibility for long-term SNM therapy by performing an external trial or peripheral nerve evaluation (PNE).

Key Points: 
  • Physicians determine a patient’s eligibility for long-term SNM therapy by performing an external trial or peripheral nerve evaluation (PNE).
  • The temporary lead that is placed during a PNE is often done in the office setting without real-time imaging (i.e., fluoroscopy).
  • The acquired technology addresses this challenge with an elegant solution comprising a software application and a hardware tool that makes PNE lead placement easier, faster, and more accurate.
  • We are confident that empowering physicians with innovative technology and tools has the potential to drive significant SNM market expansion in the years ahead.”

Axonics to Participate in the SUFU 2023 Winter Meeting

Retrieved on: 
Tuesday, March 7, 2023
Medical Supplies, Medical Devices, Health, Health Technology, General Health, Biotechnology, Role, Physician, Effectiveness, Nocturia, Overactive bladder, Patient, Fecal incontinence, Incontinence, Urinary retention, SUFU, Quality of life, SNM, Society, Winter Meeting, Durability, OAB, Pharmaceutical industry, Axon reflex

In addition, data highlighting the experience of patients with Axonics SNM therapy will include three poster presentations:

Key Points: 
  • In addition, data highlighting the experience of patients with Axonics SNM therapy will include three poster presentations:
    The Role of Age in the Effectiveness of SNM for OAB – presented by Ayman Mahdy, M.D., Ph.D.
  • Effectiveness of the Axonics SNM System in Improving Sleep Quality of Life for Patients Suffering with Nocturia – presented by Michael Kennelly, M.D.
  • Efficacy and Durability of the Predictive Programming Algorithm of the Axonics SNM System – presented by Ryan Krlin, M.D.
  • “The SUFU 2023 Winter Meeting provides an opportunity for physicians to learn more about Axonics SNM therapy and the durable symptom relief patients are experiencing, directly from their peers,” said Karen Noblett, M.D., chief medical officer of Axonics.